Fentanyl buccal - Generex Biotechnology

Drug Profile

Fentanyl buccal - Generex Biotechnology

Alternative Names: Fentanyl citrate buccal - Generex; Fentanyl oral spray - Generex

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator Generex Biotechnology Corporation
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 21 Mar 2016 This programme is still active
  • 08 Aug 2013 Biomarkers information updated
  • 10 Jan 2013 Fentanyl buccal is available for licensing as of 10 Jan 2013. http://www.generex.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top